Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Severe COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia or Indolent B-Cell Non-Hodgkin Lymphoma Who Received Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab in Italy: Preliminary Results of the Observational Study By the Gimema Working Party on Chronic Lymphoproliferative Disorders and By the Fondazione Italiana Linfomi

Blood (2024) 144 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2024-199014

Published: 2024

Journal Articles

Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Chiara Pagani, Alessandro Re, Simone Maifredi, Angela Passi, Rosa Daffini, Antonella Anastasia, Marina Motta, Samuele Bagnasco, Erika Borlenghi, Alessia Pantaleo, Chiara Aquilina, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 4473.

https://doi.org/10.1182/blood-2024-208478

Published: 2024

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Blood (2023) 142 (Supplement 1): 4690.

https://doi.org/10.1182/blood-2023-188408

Published: 2023

Journal Articles

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Blood (2023) 142 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2023-182347

Published: 2023

Journal Articles

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 982.

https://doi.org/10.1182/blood-2023-174901

Published: 2023

Journal Articles

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Blood (2023) 141 (21): 2615–2628.

https://doi.org/10.1182/blood.2022019240

Published: 2023

Includes: Supplemental data

Journal Articles

Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience

Antonella Anastasia, Chiara Pagani, Alessandro Re, Marina Motta, Giacomo Pata, Enrico Damiani, Lisa Gandolfi, Rosa Daffini, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 11951–11953.

https://doi.org/10.1182/blood-2022-164792

Published: 2022

Journal Articles

Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Blood (2022) 140 (Supplement 1): 6482–6484.

https://doi.org/10.1182/blood-2022-168712

Published: 2022

Journal Articles

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Blood (2022) 140 (Supplement 1): 1313–1315.

https://doi.org/10.1182/blood-2022-166225

Published: 2022

Journal Articles

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Blood (2021) 137 (18): 2495–2508.

https://doi.org/10.1182/blood.2020008414

Published: 2021

Includes: Supplemental data

Journal Articles

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136633

Published: 2020

Journal Articles

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

Antonio Sacco, RN, Cinzia Federico, PhD, Arianna Giacomini, PhD, Cinzia Caprio, PhD, Federica Maccarinelli, PhD, Katia Todoerti, PhD, Vanessa Favasuli, Antonella Anastasia, MD, Marina Motta, MD, Giuseppe Rossi, MD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Antonino Neri, MD, Roberto Ronca, PhD, Chiara Cattaneo, MD, Alessandra Tucci, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MDPhD

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136523

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Blood (2019) 134 (Supplement_1): 1527.

https://doi.org/10.1182/blood-2019-126889

Published: 2019

Journal Articles

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Cinzia Federico, PhD, Antonio Sacco, RN, Katia Todoerti, PhD, Arianna Giacomini, PhD, Gaia C Ghedini, PhD, Gaetana Lanzi, PhD, Marina Motta, MD, Antonella Anastasia, MD, Vanessa Favasuli, Roberto Ronca, PhD, Silvia Giliani, PhD, Nicole Bozza, PhD, Riccardo Castelli, PhD, Giuseppe Rossi, Antonino Neri, MD, Marco Mor, PhD, Marco Presta, PhD, Aldo M. Roccaro, MD PhD

Blood (2019) 134 (Supplement_1): 1822.

https://doi.org/10.1182/blood-2019-126554

Published: 2019

Journal Articles

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, MD, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, Flavia Salvi, Antonella Anastasia, MD, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, MD, Anna Marina Liberati, MD, Nicola Di Renzo, MD, Luca Castagna, MD, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2018) 132 (Supplement 1): 1628.

https://doi.org/10.1182/blood-2018-99-118931

Published: 2018

Journal Articles

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Samantha Ferrari, MD, Alessandra Tucci, Gloria Valimberti, MD, Antonella Anastasia, MD, Chiara Bottelli, MD, Marta Petullà, Marina Motta, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2018) 132 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2018-99-114896

Published: 2018

Journal Articles

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

Antonio Sacco, Loredana Affò, Gaia C Ghedini, Gaetana Lanzi, Arianna Giacomini, Marina Motta, Antonella Anastasia, Claudia Ghidini, Marco Chiarini, Silvia Giliani, Roberto Ronca, Luisa Imberti, MD, Alessandro Montanelli, MD, Nicole Bozza, Riccardo Castelli, Giuseppe Rossi, MD, Marco Mor, Marco Presta, Aldo M. Roccaro

Blood (2017) 130 (Supplement 1): 2818.

https://doi.org/10.1182/blood.V130.Suppl_1.2818.2818

Published: 2017

Journal Articles

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Armando Santoro, MD, Rita Mazza, MD, Alessandro Pulsoni, MD, Alessandro Re, Maurizio Bonfichi, MD, Vittorio Ruggero Zilioli, MD, Flavia Salvi, MD, Antonella Anastasia, Stefano Luminari, MD, Manuel Gotti, MD, Annalisa Peli, Anna Marina Liberati, MD, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella, MD

Blood (2015) 126 (23): 581.

https://doi.org/10.1182/blood.V126.23.581.581

Published: 2015

NARROW

Impact of MYC Alterations in De Novo and Transformed Large B-Cell Lymphoma: An Italian Single Center Experience

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Deciphering the Immune Microenvironment in Waldenstrom's Macroglobulinemia

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Rituximab and Lenalidomide (R 2 ) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL)

Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

Not Yet Time to Retire Splenectomy in Splenic Marginal Zone Lymphoma (SMZL): Results of a Single Center Experience

Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88

Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience

FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Waldenström's Macroglobulinemia (WM) Is Preceded By Clonal Lymphopoiesis Including MYD88 L265P in Progenitor B Cells

Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis

Five-Year Survival and Durability Results of the Phase 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine)As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Classic Hodgkin Lymphoma

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Targeting Lymphoplasmacytic Lymphoma through a Novel Anti-FGF-Based Therapeutical Strategy

Remarkable Clinical Efficacy, Stem Cell Mobilization Activity and Good Toxicity Profile of the Novel Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) Used As Salvage Therapy Prior to Autologous Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only